ArticleOpen heart2023
Impact of the COVID-19 pandemic on CVD prevention between different socioeconomic groups in Switzerland.
Article in Open heart, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic disrupted the continuing management of cardiovascular disease (CVD) risk factors in the population. Socioeconomic status (SES) is a major determinant of health. Whether the COVID-19 pandemic increased, the SES gap in CVD risk factors is unknown.
aimsTo compare the management of CVD risk factors and the SES gap before and during the pandemic.
methodsCross-sectional study conducted between 2018 and 2021 in Lausanne, Switzerland. Prevalence, awareness, treatment and control rates of hypertension, dyslipidaemia and diabetes were compared between the periods before (N=2416, 45.2% men, 65.3±9.8 years) and during (N=776, 44.5% men, 63.9±9.1 years) the COVID-19 pandemic. SES was defined by education and categorised as low (compulsory or apprenticeship), middle (high school) and high (university).
resultsAfter multivariable analysis, the prevalence of hypertension increased, and awareness decreased during the pandemic: OR and (95% CI) 1.26 (1.04 to 1.53) and 0.70 (0.53 to 0.94), respectively. For dyslipidaemia, prevalence decreased during the pandemic 0.82 (95% CI 0.69 to 0.98); awareness did not change. For diabetes, prevalence did not change but awareness increased 5.76 (95% CI 1.23 to 27.04). No differences were found before and during the pandemic regarding treatment and control for all CVD risk factors. Relative to high SES, a decrease in hypertension awareness among middle SES categories was observed during the pandemic (OR and 95% CI 1.11 (0.73 to 1.69) before and 0.45 (95% CI 0.23 to 0.85) during, p for interaction<0.05), while no other changes were found.
conclusionPrevalence and management of CVD risk factors changed little during the pandemic. The SES gap did not increase except for hypertension awareness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.